ClinicalTrials.gg

Program

trosunilimab

Also written as “Trosunilimab” and “ABBV-382”.

Its studies are mostly in Crohn Disease · Acquired Immunodeficiency Syndrome, led by AbbVie.

Furthest: phase 2, since Sep 5, 20236 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie63 open or runningphase 2since Sep 5, 2023Sep 14, 2020May 2027phase 1 · NCT07925983

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2020First study: phase 1 study in Acquired Immunodeficiency SyndromeFirst studyNCT04554966 · 54 enrolled · United States, Puerto Rico
  2. Sep 5, 2023Phase 2 study in DiseaseNCT06032546 · 163 enrolled · United States, Belgium, Brazil and more
  3. Aug 8, 2024Phase 2 study in Crohn DiseaseNCT06548542 · 590 planned · United States, Austria, Belgium and more
  4. Oct 8, 2024Phase 1 study in Healthy VolunteerNCT06632938 · 24 enrolled · China
  5. Jul 7, 2026Phase 2 study in Crohn DiseaseNCT07697456 · 2,000 planned · United States, Canada, Israel and more
  6. Oct 21, 2026Phase 1 study in Healthy VolunteerNCT07925983 · 60 planned · United States

Ahead

  1. May 2027Primary completion: phase 1 study in Healthy VolunteerNCT07925983
  2. Jan 2030Primary completion: phase 2 study in Crohn DiseaseNCT06548542
  3. Oct 2031Primary completion: phase 2 study in Crohn DiseaseNCT07697456

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07925983Healthy Volunteer · United States1RecruitingMay 202760
NCT07697456Crohn Disease · United States, Canada, Israel and more2RecruitingOct 20312,000
NCT06632938Healthy Volunteer · China1CompletedMay 15, 202524
NCT06548542Crohn Disease · United States, Austria, Belgium and more2RecruitingJan 2030590
NCT06032546Disease · United States, Belgium, Brazil and more2TerminatedSep 22, 2025163
NCT04554966Acquired Immunodeficiency Syndrome · United States, Puerto Rico1CompletedAug 14, 202354

How it is read

Names in the registry

  • “Trosunilimab”, 5 entries
  • “ABBV-382”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.